Physician profile
David Qi
NPI 1760826952
$4,161.56
in general payments reported to CMS, 2019-2025
30 companies · $73.56 in 2025
The $73.56 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $653 · 2021: $1,193 · 2022: $566 · 2023: $626 · 2024: $595 · 2025: $73.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.38 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $789.22 | 2019-2024 | Xiaflex |
| Boston Scientific Corporation | $623.23 | 2019-2024 | Ams 700, Advance Xp |
| Medtronic, INC. | $477.00 | 2021-2024 | Interstim |
| Zyla Life Sciences, INC. | $368.19 | 2019-2020 | |
| Urogen Pharma, INC. | $278.44 | 2021-2025 | Jelmyto |
| Coloplast Corp | $184.77 | 2020-2024 | Speedicath |
| Axonics, INC. | $177.78 | 2021-2023 | Axonics |
| Medtronic USA, INC. | $153.28 | 2020 | |
| Antares Pharma, INC. | $121.10 | 2021-2024 | Xyosted |
| Pfizer INC. | $93.64 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $83.78 | 2023-2024 | Gemtesa |
| Abbvie INC. | $79.09 | 2023 | |
| Neotract INC. | $77.48 | 2019 | |
| Procept Biorobotics Corporation | $66.94 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Hollister Incorporated | $64.28 | 2021-2023 | Onli, Infyna Chic |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $61.51 | 2021 | |
| Astellas Pharma US INC | $57.35 | 2021-2023 | Myrbetriq |
| Urovant Sciences INC | $53.79 | 2021-2022 | |
| Allergan, INC. | $51.99 | 2021 | |
| Verity Pharmaceuticals INC. | $46.18 | 2024-2025 | Trelstar, Tlando |
| Tolmar Pharmaceuticals, INC. | $37.26 | 2019-2022 | |
| Endo USA, INC. | $35.16 | 2024 | Xiaflex |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Halozyme INC | $29.08 | 2023 | |
| Karl Storz Endoscopy-America | $25.07 | 2024 | |
| Alexion Pharmaceuticals, INC. | $21.91 | 2023 | Soliris |
| Myriad Genetic Laboratories, INC. | $19.75 | 2021 | |
| Laborie Medical Technologies Corp. | $16.78 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Dendreon Pharmaceuticals LLC | $16.55 | 2019 | |
| Ethicon US, LLC | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Qi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.